BVT Call 120 MRK 20.12.2024/ DE000VC06F59 /
08/11/2024 20:04:43 | Chg.+0.003 | Bid21:47:38 | Demandez à20:04:43 | Sous-jacent | Prix d'exercice | Date d'expiration | Type d'option |
---|---|---|---|---|---|---|---|
0.007EUR | +75.00% | - Bid taille: - |
- Ask la taille: - |
Merck and Co Inc | 120.00 USD | 20/12/2024 | Call |
GlobeNewswire
31/07
Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
GlobeNewswire
17/07
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease a...
GlobeNewswire
11/06
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next...
GlobeNewswire
06/06
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepin...
GlobeNewswire
28/05
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
GlobeNewswire
23/05
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
GlobeNewswire
16/05
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
14/05
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
GlobeNewswire
08/05
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
24/04
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Onc...
GlobeNewswire
15/04
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
- La première page
- Retour
- 1
- 2
- 3
- 4
- Suivant
- La dernière page